switching from tirzepatide to semaglutide dosage for weight loss semaglutide dose vs tirzepatide dose Semaglutide & Tirzepatide: Weight Loss in Rancho Santa Fe transitioning from tirzepatide to semaglutide

Pharmaceutical GLP-1 receptor agonists are considered for type 2 diabetes or obesity with specific criteria under NICE guidance, typically within specialist services

In the first year following diagnosis, we found increased cumulative incidence risk ratios in a number of outcomes including: - Any mental, behavioural, or neurodevelopmental disorder 1.96 (1.93 - 1.99) - Postpartum depression 2.70 (2.61 - 2.79) - Eating disorders 2.06 (1.85 - 2.89) - PTSD 1.77 (1.69 - 1.86) We also saw significantly increased risk in rare but serious outcomes such as: - Wernicke's encephalopathy 2.39 (1.25 - 4.56) - Puerperal psychosis 1.80 (1.48 - 2.20) Interestingly, cases of hyperemesis gravidarum with metabolic disturbance displayed a significantly lower risk of any depression and postpartum depression compared with those without metabolic disturbance

Grip strength declining 38 kg from baseline often months before any change appears on a body composition scan

Stopping GLP-1s often leads to weight regain and increased appetite

those on licensed hair loss treatments should consult a healthcare professional before adding them